Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Galena Biopharma Inc (GALE), Oncolytics Biotech, Inc. (USA) (ONCY): 2 Drugs With Acquisition Potential

Page 1 of 2

Big pharmaceutical players, known as Big Pharma, depend on patents to fend of generic threats to their blockbuster drugs. So when a patent expires, cheaper generic products flood the market. The sales of the premium drug take a nose dive once similar compounds are available at cheaper rates.

Therefore, it is imperative for big-pharmaceutical players to continue the hunt for new candidates. In this lies the enormous potential of small biotechnology companies with promising candidates.

Patent cliff

The entire healthcare sector is heading towards a patent cliff. Blockbuster drugs like Lipitor and Seroquel IR are facing generic threats. Amongst the Big Pharma players, AstraZeneca plc (ADR) (NYSE:AZN) has suffered the most due to patent expirations. This is primarily because the company has a weak pipeline as compared to other leading players. If we look at the rest of the industry, Pfizer Inc. (NYSE:PFE) has an extremely strong pipeline while Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) already thrives in the generic space.

AstraZeneca plc (ADR) (NYSE:AZN) has recently announced that it is buying fish-oils drug maker Omthera for $443 million. The new CEO, Pascal Soriot, had earlier announced that he wishes to strengthen cardiovascular, cancer and respiratory pipelines. This acquisition increases chances that the cash rich AstraZeneca plc (ADR) (NYSE:AZN) will make an oncology related purchase next. The following biotechnology companies are working on some promising oncology candidates and have the ability to attract leading players like AstraZeneca plc (ADR) (NYSE:AZN).

Galena Biopharma Inc

Cancer vaccine

Galena Biopharma Inc (NASDAQ:GALE) is a biotechnology company which is involved in the discovery, development, commercialization and acquisition of pharmaceutical products. The primary candidate of Galena Biopharma Inc (NASDAQ:GALE)is NeuVax,  a vaccine for the prevention of breast cancer. The vaccine is in Phase III of global trials, assessing breast cancer recurrence in early stages. The combination of Herceptin and NeuVax for breast cancer is in Phase II trials. The vaccine is also in Phase II trials for prevention of prostate cancer.

In a recent move, Galena Biopharma Inc (NASDAQ:GALE) has acquired U.S. rights for Abstral. The drug received FDA approval back in 2011 as a relief for cancer pain. According to reports, the U.S. market for TIRFs, such as Abstral, is around $400 million.

Galena Biopharma Inc (NASDAQ:GALE) has a market capitalization of around $200 million and is also trading at a 100% discount to its mean sell-side target price of $4.90. It is a perfect fit for any company looking to expand its oncology portfolio. At current valuations it can be a perfect fit for AstraZeneca, which is looking to strengthen its Oncology franchise.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!